|
1
|
Mock V, Atkinson A, Barsevick AM, Berger
AM, Cimprich B, Eisenberger MA, Hinds P, Kaldor P, Otis-Green SA
and Piper BF: Cancer-related fatigue. Clinical practice guidelines
in oncology. J Natl Compr Canc Netw. 5:1054–1078. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Glaspy J: Anemia and fatigue in cancer
patients. Cancer. 92 Suppl 6:S1719–S1724. 2001. View Article : Google Scholar
|
|
3
|
Foster DW: The role of the carnitine
system in human metabolism. Ann N Y Acad Sci. 1033:1–16. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cruciani RA, Dvorkin E, Homel P, Culliney
B, Malamud S, Shaiova L, Fleishman S, Lapin J, Klein E, Lesage P,
et al: L-carnitine supplementation for the treatment of fatigue and
depressed mood in cancer patients with carnitine deficiency: A
preliminary analysis. Ann N Y Acad Sci. 1033:168–176. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Graziano F, Bisonni R, Catalano V, Silva
R, Rovidati S, Mencarini E, Ferraro B, Canestrari F, Baldelli AM,
De Gaetano A, et al: Potential role of levocarnitine
supplementation for the treatment of chemotherapy-induced fatigue
in non-anaemic cancer patients. Br J Cancer. 86:1854–1857. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Waldner R, Laschan C, Lohninger A, Gessner
M, Tüchler H, Huemer M, Spiegel W and Karlic H: Effects of
doxorubicin-containing chemotherapy and a combination with
L-carnitine on oxidative metabolism in patients with non-Hodgkin
lymphoma. J Cancer Res Clin Oncol. 132:121–128. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bianchi G, Vitali G, Caraceni A, Ravaglia
S, Capri G, Cundari S, Zanna C and Gianni L: Symptomatic and
neurophysiological responses of paclitaxel- or cisplatin-induced
neuropathy to oral acetyl-L-carnitine. Eur J Cancer. 41:1746–1750.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hockenberry MJ, Hooke MC, Gregurich M and
McCarthy K: Carnitine plasma levels and fatigue in
children/adolescents receiving cisplatin, ifosfamide, or
doxorubicin. J Pediatr Hematol Oncol. 31:664–669. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gramignano G, Lusso MR, Madeddu C, Massa
E, Serpe R, Deiana L, Lamonica G, Dessì M, Spiga C, Astara G, et
al: Efficacy of l-carnitine administration on fatigue, nutritional
status, oxidative stress and related quality of life in 12 advanced
cancer patients undergoing anticancer therapy. Nutrition.
22:136–145. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mendoza TR, Wang XS, Cleeland CS,
Morrissey M, Johnson BA, Wendt JK and Huber SL: The rapid
assessment of fatigue severity in cancer patients: Use of the brief
fatigue inventory. Cancer. 85:1186–1196. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Okuyama T, Wang XS, Akechi T, Mendoza TR,
Hosaka T, Cleeland CS and Uchitomi Y: Validation study of the
Japanese version of the brief fatigue inventory. J Pain Symptom
Manage. 25:106–117. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dodson WL, Sachan DS, Krauss S and Hanna
W: Alterations of serum and urinary carnitine profiles in cancer
patients: Hypothesis of possible significance. J Am Coll Nutr.
8:133–142. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Peluso G, Nicolai R, Reda E, Benatti P,
Barbarisi A and Calvani M: Cancer and anticancer therapy-induced
modifications on metabolism mediated by carnitine system. J Cell
Physiol. 182:339–350. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brass EP, Adler S, Sietsema KE, Hiatt WR,
Orlando AM and Amato A; CHIEF Investigators, : Intravenous
L-carnitine increases plasma carnitine, reduces fatigue and may
preserve exercise capacity in hemodialysis patients. Am J Kidney
Dis. 37:1018–1028. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
McNeil C: Cancer fatigue: One drug fails
but more are in the pipeline. J Natl Cancer Inst. 93:892–893. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ringseis R, Keller J and Eder K:
Mechanisms underlying the anti-wasting effect of L-carnitine
supplementation under pathologic conditions: Evidence from
experimental and clinical studies. Eur J Nutr. 52:1421–1442. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fatouros IG, Douroudos I, Panagoutsos S,
Pasadakis P, Nikolaidis MG, Chatzinikolaou A, Sovatzidis A,
Michailidis Y, Jamurtas AZ, Mandalidis D, et al: Effects of
L-carnitine on oxidative stress responses in patients with renal
disease. Med Sci Sports Exerc. 42:1809–1818. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cruciani RA, Dvorkin E, Homel P, Culliney
B, Malamud S, Lapin J, Portenoy RK and Esteban-Cruciani N:
L-carnitine supplementation in patients with advanced cancer and
carnitine deficiency: A double-blind, placebo-controlled study. J
Pain Symptom Manage. 37:622–631. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Iwase S, Kawaguchi T, Yotsumoto D, Doi T,
Miyara K, Odagiri H, Kitamura K, Ariyoshi K, Miyaji T, Ishiki H, et
al: Efficacy and safety of an amino acid jelly containing coenzyme
Q10 and L-carnitine in controlling fatigue in breast cancer
patients receiving chemotherapy: A multi-institutional, randomized,
exploratory trial (JORTC-CAM01). Support Care Cancer. 24:637–646.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Malaguarnera M, Vacante M, Giordano M,
Pennisi G, Bella R, Rampello L, Malaguarnera M, Li Volti G and
Galvano F: Oral acetyl-L-carnitine therapy reduces fatigue in overt
hepatic encephalopathy: A randomized, double-blind,
placebo-controlled study. Am J Clin Nutr. 93:799–808. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cruciani RA, Zhang JJ, Manola J, Cella D,
Ansari B and Fisch MJ: L-carnitine supplementation for the
management of fatigue in patients with cancer: An eastern
cooperative oncology group phase III, randomized, double-blind,
placebo-controlled trial. J Clin Oncol. 30:3864–3869. 2012.
View Article : Google Scholar : PubMed/NCBI
|
